786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA

by sugaradmin



Introduction and Objective: Persistence with the injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for weight management has been studied extensively, but drivers of persistence are not well characterized. We sought to identify predictors of persistence in a US real-world population.Methods: Adults (≥18 years old) who had a first claim for semaglutide for weight management (index date) between June 4, 2021 and July 1, 2023 were identified in the IQVIA Ambulatory Electronic Medical Records database, linked to PharMetrics® Plus. Individuals required ≥1 year of continuous enrollment pre-index and ≥1 year of follow-up data. Individuals with previous bariatric surgery were excluded. Discontinuation was indicated by >90 days not covered by the medication. Factors associated with persistence were identified using logistic regression.Results: In total, 42,028 individuals were included. Overall, 78.9% were women and 85.5% were aged ≥35 years; 39.5% had hypertension and 9.4% had T2D. At month 12, 38% were persistent on semaglutide. Predictors associated with persistence (p<0.05) were previous use of liraglutide for weight management (odds ratio [OR] 1.69), age ≥35 years (OR 1.63), and, among people with diabetes, use of other GLP-1RAs (OR 1.21). The following factors were negatively associated with persistence (p<0.05): male sex (OR 0.93), previous use of phentermine (OR 0.87), insulin use in people with diabetes (OR 0.79), and preexisting comorbidities (OR: musculoskeletal pain, 0.95; cerebrovascular disease, 0.84; ischemic heart disease, 0.84; T2D, 0.79; peripheral artery disease, 0.73).Conclusion: In a US real-world population, familiarity with the GLP-1RA class of medications appeared to help with persistence. An additional focus for obesity management with semaglutide should be to provide guidance on what to expect on the treatment journey, in particular for patients at higher risk of discontinuing treatment.

Disclosure

W.H. Polonsky: Consultant; Abbott. Research Support; Abbott. Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. Other Relationship; Ascensia Diabetes Care. R. Arora: Employee; Novo Nordisk, IQVIA Inc. J. Fernandes: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. T. Arnaut: Employee; Novo Nordisk A/S, Roche Diabetes Care.



Source link